Pacira BioSciences heads into its Q1 2026 earnings release — due after the close today — with two colliding stories: a meaningful short-covering wave over the past week, and an active proxy battle with a dissident shareholder that the market is still weighing.
The positioning shift is the clearest signal right now. Short interest has dropped sharply this month. From a peak near 22.8% of the free float in early April, shorts have covered roughly 1.1 million shares, bringing SI down to 19.7% of float as of Wednesday. That 9% week-on-week decline in shares short is the single largest directional move in the 30-day window. It doesn't signal a sudden change of heart on PCRX's fundamentals — a name this heavily shorted ($185M in estimated short value based on available float data) rarely shifts that fast for fundamental reasons. More likely, shorts are trimming ahead of the earnings release and an annual meeting battle that introduces binary outcomes.
The borrow market tells a consistent story. Availability remains well-stocked — there is no squeeze dynamic in play. Cost to borrow ticked up 28% on the week to 0.58% annually, which sounds alarming but remains trivially cheap in absolute terms; this is still an easy stock to borrow and shorts face no meaningful financing pressure to close positions. The options market adds another layer to the picture: the put/call ratio has actually drifted lower, sitting at 0.31 — well below its 20-day average of 0.36 and nearly 1.6 standard deviations on the bullish side. That means options traders are running lighter on downside protection than they have been all month, a notable contrast to a stock heading into an uncertain binary event.
The Street has not been enthusiastic. The most recent analyst action came from Barclays in late March, trimming its target from $27 to $25 while holding an Equal-Weight rating — essentially flagging the stock as range-bound near current levels. Holding Buy ratings, Needham and HC Wainwright have targets of $30 and $38 respectively, but both reaffirmations date to early January and are now over three months stale relative to today. The consensus mean target of $28.71 implies modest upside from the current $25.14 close — encouraging but not compelling enough to push the stock materially higher on its own. Valuation multiples are undemanding: EV/EBITDA at 6.3x has drifted down modestly over the past month, and a PE of 8.6x is low for a pharma company still generating positive earnings. The EPS 12-month forward YoY increase factor ranks in the 96th percentile — the company's earnings trajectory looks better than almost all of its peers on a forward basis, even as the trailing EPS surprise score (11th percentile) suggests the company has a habit of coming in below expectations.
The more unusual angle this week is the proxy fight. DOMA Perpetual Capital Management — holding roughly 4.9% of PCRX — has filed a PRRN14A this morning, a contested proxy statement. Pacira itself filed definitive proxy materials on Tuesday and mailed a letter to shareholders pushing back. This kind of contested annual meeting introduces a layer of event risk that sits orthogonally to the Q1 earnings print: even a clean beat may not resolve the underlying corporate governance dispute. DOMA has held its position flat through at least the most recent reporting period, while Renaissance Technologies trimmed ~254,000 shares and Balyasny cut nearly its entire 939,000-share position in the December quarter.
On the operational news side, Pacira published real-world data this week showing EXPAREL reduced opioid use and lowered total medical costs in Medicare patients undergoing total hip arthroplasty — incremental evidence supporting the drug's value proposition in outpatient surgical settings, which is central to the bull case. Bears remain focused on EXPAREL's age (14 years on market), the generic competition risk, and the binary nature of PCRX-201 — the company's early-stage gene therapy for knee osteoarthritis.
The Q1 print after the close today is the immediate catalyst. The last earnings release in February produced a 6.6% single-day decline. That prior reaction, combined with a still-elevated short position and an unresolved proxy contest, means the post-earnings setup involves more moving parts than usual — what to watch is not just the revenue line but whether management provides any clarity on how the DOMA dispute gets resolved.
See the live data behind this article on ORTEX.
Open PCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
